Clinical trials: Placebo-Post
Type 2 Diabetes Mellitus
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of…
- Trial name
- NCT01144338
- Testing
- Exenatide Once Weekly
- Where
- 629 sites in United States, Argentina and 33 more
- Volunteers
- 14,752 people
- Sponsor
- AstraZeneca
Acute Pain
Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride
This study aims to evaluate the analgesic efficacy of single and repeated doses of fixed combination of dexketoprofen trometamol (DKP) and tramadol hydrochloride (TRAM) in comparison to the single agents (and placebo for the…
- Trial name
- DAVID lap (NCT01904149)
- Testing
- Dexketoprofen-single dose, Tramadol-single dose, Dexketoprofen/Tramadol-single dose
- Where
- 28 sites in Hungary, Latvia and 6 more
- Volunteers
- 606 people
- Sponsor
- Menarini Group
Hepatocellular Carcinoma
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or…
- Trial name
- NCT03867084
- Testing
- Pembrolizumab
- Where
- 249 sites in United States, Argentina and 29 more
- Volunteers
- 959 people
- Sponsor
- Merck Sharp & Dohme LLC
Post-surgical Dental Pain
Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain
The purpose of this study is to evaluate the overall pain relief of a single dose of PF-04531083 against placebo following third molar extraction.
- Trial name
- NCT01512160
- Testing
- PF-04531083, Ibuprofen
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Healthy, Primary Immune Thrombocytopenia
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP).
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Trial name
- NCT03275740
- Testing
- PF-06755347 intravenous healthy participant, PF-06755347 subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
- Trial name
- STORM CHASER (NCT04625972)
- Testing
- AZD7442
- Where
- 57 sites in United States, United Kingdom
- Volunteers
- 1,131 people
- Sponsor
- AstraZeneca
Plaque Psoriasis
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
- Trial name
- ObePso-S (NCT03055494)
- Testing
- Secukinumab
- Where
- 15 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Fungal Rhinosinusitis
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS). Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in…
- Trial name
- ADAPT (NCT05545072)
- Testing
- Dupilumab, Intranasal Corticosteroid Sprays (INCS)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Post-Traumatic Headache
A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of fremanezumab in adult participants aged 18 to 70 years, inclusive, for the prevention of PTH.
- Trial name
- NCT03347188
- Testing
- Fremanezumab
- Where
- 33 sites in United States
- Volunteers
- 87 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bunion, Pain
Intravenous Tapentadol in Post-Bunionectomy Pain
The purpose of this trial is to established the safety and efficacy of multiple dose treatment with tapentadol IV in an adult population with moderate to severe pain following bunionectomy.
- Trial name
- NCT01435577
- Testing
- Tapentadol
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Grünenthal GmbH
Amyotrophic Lateral Sclerosis
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
- Trial name
- VITALITY-ALS (NCT02496767)
- Testing
- Tirasemtiv
- Where
- 81 sites in United States, Belgium and 9 more
- Volunteers
- 744 people
- Sponsor
- Cytokinetics
Acute Pain
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after a bunionectomy.
- Trial name
- NCT04977336
- Testing
- VX-548, HB/APAP
- Where
- 12 sites in United States
- Volunteers
- 274 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Postoperative Nausea and Vomiting
Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV.
- Trial name
- NCT00895830
- Testing
- APD405
- Where
- 18 sites in United States, France and 2 more
- Volunteers
- 257 people
- Sponsor
- Acacia Pharma Ltd
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Paxlovid for Treatment of Long Covid
The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid.
- Trial name
- STOP-PASC (NCT05576662)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Stanford University
Myocardial Infarction, Acute, Heart Failure, Left Sided
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction…
- Trial name
- HF-REVERT (NCT05350969)
- Testing
- CDR132L
- Where
- 49 sites in Czechia, Germany and 6 more
- Volunteers
- 294 people
- Sponsor
- Cardior Pharmaceuticals GmbH
Autism Spectrum Disorder (ASD)
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.
- Trial name
- NCT03715153
- Testing
- BUMETANIDE (S95008) for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 211 people
- Sponsor
- Institut de Recherches Internationales Servier
Hypersensitivity, Anaphylaxis
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
The purpose of this study is to assess the potential for hypersensitivity symptoms upon repeat exposure to sugammadex. Healthy participants will be randomized to one of three treatment arms: sugammadex 4 mg/kg, sugammadex 16…
- Trial name
- NCT02028065
- Testing
- Sugammadex
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pain, Post-operative
Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery
The primary objective of this study is to evaluate the safety of N1539 in subjects with acute moderate to severe pain following unilateral bunionectomy.
- Trial name
- NCT02540265
- Testing
- N1539
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Baudax Bio
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a…
- Trial name
- NCT02443077
- Testing
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 281 sites in United States, Saudi Arabia
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndromes
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride, a modulator of multidrug resistance (MDR), may help daunorubicin and cytarabine…
- Trial name
- NCT00046930
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 92 sites in United States, Israel
- Volunteers
- 449 people
- Sponsor
- Eastern Cooperative Oncology Group